

CiplaQCi

CIPLA QUALITY CHEMICAL
INDUSTRIES LIMITED

ACCESS TO QUALITY AFFORDABLE MEDICINES



Cipla Quality Chemical Industries Limited
Plot 1-7, 1st Ring Road, Luzira Industrial Park,
P.O. Box 34871, Kampala.
Tel: +256 312 341 100 | Fax: +256 414 221 319
Web: www.ciplaqcil.co.ug

About us

Cipla Quality Chemical Industries Limited (CiplaQCIL) is a state of the art pharmaceutical plant that manufactures the latest Anti-retroviral (ARVs) and Anti-malarial (ACTs) medicines. CiplaQCIL was established in 2005 as a joint venture company between Cipla Ltd of India, the world's largest manufacturer of generic medicines and Quality Chemicals (QCL) Ltd of Uganda. The venture attracted two other international investors namely; Capitalworks Investment and TLG Capital Investments of Mauritius. In 2013, QCL entered into a strategic partnership with Cipla where the Indian company acquired more shares in an effort to enhance technology and knowledge transfer. The establishment of the pharmaceutical plant is in line with the Pharmaceutical Manufacturing Plan of Action for Africa, the East African Pharmaceutical Manufacturing Plan of Action and the Millenium Development Goals. The plant seeks to take advantage of the flexibilities provided by the Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS), for access to affordable, newer and safer medicines for the poor. CiplaQCIL's World Health Organization (WHO) approved facility stands as a testament to the possibilities of pharmaceutical manufacturing in Africa.



We give hope for a healthier life

Our Vision

To become a center of excellence in the manufacturing of quality, affordable and newer medicines.

Our Mission

To sustainably avail affordable and efficacious medicines in order to improve the quantity and quality of life.

Our Values

At CiplaQCIL, we ensure that every decision and action we take demonstrates our values. The team is guided by six core values that create lasting benefits for the clients we serve. We strive to ensure:

- Quality and Excellence
- Customer focus
- Integrity
- Teamwork
- Accountability
- Innovation



Providing Quality Affordable Medicines

Our focus has been on HIV/AIDS and Malaria as these are the biggest health challenges of the century in Africa. Africa has over 60% of all HIV/AIDS cases and 80% of the global malaria cases but it manufactures only 2% of the required medicines. While these diseases have caused devastation to many families and communities in Africa, the impact has been compounded by lack of access to expensive medicines. We therefore made the decision to meet the overwhelming need of the many by manufacturing quality and affordable medicines to combat these diseases.

Also as the company continues on its growth trajectory, we are now broadening our scope of products in order to address other diseases. We want to ensure that people have a sustainable access to newer, safer and affordable quality medicines by continuously innovating and adding more product lines to meet the needs of our customers.

The Facility

The over USD 70 million plant has been designed to meet the world's most stringent regulatory standards. It sits on 12 acres of land located 12km east of Kampala, Uganda and has a built up area of 14,000 square metres. The facility manufactures 80 million tablets a month and plans are underway to increase its production capacity to 100 million tablets a month. The facility produces complex molecules of various fixed dose medicines for the management of Malaria and HIV/AIDS. The goal of the design specifications for CiplaQCIL is to produce pharmaceutical products of the highest quality that have zero environmental impact, adhere to current Good Manufacturing Practices (cGMP), Good Laboratory Practices (GLP), and international regulatory standards.



Our Products

CiplaQCIL has so far specialized in the manufacture of Anti-retrovirals and new anti-malarial drugs known as Artemisinin-based Combination Therapies (ACTs).

Product name	Active Ingredients (Strength)	Pack size
ACT Products		
Lumartem	Artemether – 20mg Lumefantrine – 120mg	6x1, 6x2, 18x1, 24x1 blisters 6x30,12x30,18x30 and 24x30
ARV Products		
Duovir – N	Lamivudine USP – 150mg, Zidovudine USP – 300 mg,	60's container Nevirapine USP – 200mg
Efavir 600	Efavirenz 600mg	30's container
Duovir	Lamivudine USP – 150mg, Zidovudine USP – 300mg	60's container
Nevimune 200	Nevirapine USP – 200mg	60's container
Duomune	Tenofovir Disoproxil Fumarate – 300mg, Lamivudine USP – 300mg	30's container
Trioday	Lamivudine – 300mg, Tenofovir Disoproxil Fumarate – 300mg, Efavirenz – 600mg	30's container



Future Products

CiplaQCIL is soon introducing other ACTs and medicines that treat Hepatitis B and parasitic worms.

Active Ingredients	Strength	Disease
Albendazole	400mg	Parasitic worms
Tenofovir Disoproxil Fumerate	300mg	Hepatitis B Virus
Entacavir	0.5mg and 1mg	Hepatitis B Virus
Lamivudine	100mg	Hepatitis B Virus
Artesunate and Mefloquine		Malaria
Artesunate and Amodiaquine		Malaria

Major Milestones

The plant and the medicines produced at CiplaQCIL have been approved by:

- World Health Organization (WHO)
- National Drug Authority (NDA)
- International Committee of the Red Cross (ICRC)
- Drugs for Neglected Diseases Initiative (DNDI)
- Kenya Pharmacy and Poisons Board (KPPB)
- Tanzania Food and Drugs Administration (TFDA)
- Rwanda Biomedical Centre (RBC)
- Malawi PMPB
- Ethiopia FMHACA
- Namibia Ministry of Health
- Ivory Coast Ministry of Health



QCIL directly employs over 200 people and another 1000 indirectly



Enhancing research and development into newer medicines

CiplaQCIL's Benefits

- Improved access to essential medicines
- More affordable quality and efficacious medicines
- Reduced dependency on expensive non-generic medicines
- Enhanced research and development in pharmaceuticals
- Ensured quality due to stringent regulatory standards
- Trained workforce in specialist pharmaceutical fields



Awards & Recognitions

Cipla Quality Chemical Industries has been locally and globally recognized for the various contributions to the building of the social and economic landscape in East Africa.

- Transformational Business of the Year at the 2012 African Awards for Entrepreneurship
- 2012 African Business Leadership Award (ABLA)
- Recognized by Ministry of Health in 2012 for outstanding contribution to the development of the pharmaceutical industry
- Winner at the Ernst & Young 2011 Young Entrepreneur of the Year Award in the Master Category
- Winner of the Ernst & Young Award 2011 in the Emerging Entrepreneur Eastern Africa category
- Investor of the Year at the 2007 Uganda Investment Authority Awards

Corporate Social Responsibility

Cipla Quality Chemical Industries has adopted best practices in Corporate Social Responsibility (CSR) guided by the principle of shared values and partnerships. Our CSR initiatives focus on the environment, workplace environment, health and education, all with attention to the community in which we operate.

CiplaQCIL provides training to graduates through internship opportunities as part of its Education initiatives. Interns are given training mainly in the fields of pharmacology, biochemistry, engineering and environmental science. We also entered an understanding with a neighbourhood community school, Bishop Cipriano Kihangire Senior Secondary

School in Luzira for holiday employment and mentorship. Under the arrangement, CiplaQCIL takes on the best two science students in S.6; a boy and a girl, in a bid to encourage sciences in schools, a policy being promoted by the government.

Annually, CiplaQCIL participates in national AIDS and Malaria Days activities in support of Ministry of Health by taking part in healthcare awareness campaigns.

CiplaQCIL has also been an active member of the Uganda Corporate League covering 43 corporate organizations with the objective of bringing together communities through sport and improving health related performance at work in the process. CiplaQCIL has been the overall winner of this League for three consecutive years: 2011, 2012 and 2013.

